Menu
Recruiting NCT06620770

Impact of the Therapeutic Education Program "living with a Chronic Inflammatory Disease Under Biotherapy" on Patient Compliance and Quality of Life

Observational Chronic Inflammatory Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: questionnaires.
Who it may be relevant to
Registry conditions: Chronic Inflammatory Disease. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Impact of the Therapeutic Education Program "living with Chronic Inflammatory Disease Under Biotherapy" on Compliance and Quality of Life of Patients

Overview

Patient therapeutic education programs have been shown to be effective in many specialties, allowing "Improving biological and psychological parameters, allowing patients to improve their health knowledge, therapeutic adherence and sense of personal effectiveness." Several studies have shown that patient knowledge, adherence and satisfaction are better after attending a therapeutic education program. This multidisciplinary program is presented and offered to all patients with chronic disease treated by subcutaneous biotherapy, followed by dermatologists, rheumatologists and gastroenterologists of the Lorient hospital. The study aims to demonstrate the benefit of the Patient Therapeutic Education program at GHBS Lorient "living with a chronic inflammatory disease under biotherapy" on treatment adherence, as well as the positive impact on quality of life.

Detailed description

All patients followed up as part of their chronic disease and treated with subcutaneous biotherapy in the dermatology, rheumatology, hepatotherapygastroenterology, will be offered participation in the therapeutic education program by GHBS specialists. Whether they agree to participate or not, doctors will offer them participation in the IMPEBIO study.

Patients treated with subcutaneous biotherapy who do not wish to participate in the program will be included in the control group.

Patients treated with subcutaneous biotherapy who wish to participate in this program will be included in the intervention group. The therapeutic education program will begin within 3 months of inclusion.

If the patient does not object, the Morisky scale and the SF 12 questionnaire will be given to him. It may be assisted with filling if necessary by a clinical researcher.

Patients will first complete the Morisky test, and the quality of life questionnaire SF 12 at inclusion in the IMPEBIO study (J0), then to M6 (6 months), M12 (12 months) and M18 (18 months).

These questionnaires will then be retrieved, anonymized and sent to the investigation department. The analysis of questionnaires will not lead to changes in patient management.

Estimated time to complete the questionnaires is 10 minutes.

Interventions

  • Other questionnaires
    Morisky and SF12 Questionnaires delivery at inclusion, 6, 12 and 18 months

Primary outcome measures

  • Scores of the Morisky scale [Time frame: 18 months after inclusion]
Secondary outcome measures (2)
  • Scores of the Morisky scale [Time frame: 6 and 12 months after inclusion]
  • SF-12 quality of life questionnaire [Time frame: 6 and 12 and 18 months after inclusion]

Eligibility criteria

Inclusion criteria

  • All major patients followed up on GHBS for chronic inflammatory disease treated with S/C biotherapy.
  • Patients not opposed to their participation in the research.
  • Less than 3 months between inclusion and start of Therapeutic Education Program.

Exclusion criteria

  • Subcutaneous injection by another person.
  • Patients with cognitive impairment.
  • Persons of legal age who are the subject of a legal protection (safeguarding of justice, curatorship, guardianship), persons deprived of liberty.
  • Pregnant women.
  • Persons not covered by social security.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-control

Study locations

France · 1 center
  • Groupe Hospitalier de Bretagne Sud — Lorient

Identifiers

NCT: NCT06620770 · 56LORC_2023_IMPEBIO

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗